Gold prices cool after hitting over 2-week high on Fed independence fears
CHICAGO - Tempus AI , Inc. (NASDAQ:TEM) reported fourth quarter results Monday, following which shares were down 7% in after-hours trading.
The artificial intelligence-powered precision medicine company posted revenue of $200.7 million for the quarter ended December 31, 2024, up 35.8% YoY . Adjusted loss per share came in at $0.18, narrower than the $1.58 loss reported in the same quarter last year.
Tempus said its genomics business generated $120.4 million in Q4 revenue, up 30.6% YoY, while data and services revenue grew 44.6% to $80.2 million.
"Our performance in 2024 reflects the strength of our core businesses, as Genomics continued to show strong volume growth and our Data business delivered record results throughout the year," said Eric Lefkofsky, Founder and CEO of Tempus.
For the full year 2025, Tempus expects revenue of approximately $1.24 billion, representing 79% annual growth. The company also anticipates achieving positive adjusted EBITDA of $5 million in 2025, an improvement of about $110 million over 2024.
Tempus ended 2024 with $940 million in total remaining contract value and 140% net revenue retention. The company completed its acquisition of Ambry Genetics on February 3, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.